Peptide Library

In clinical trials

Digestive & weight

Apraglutide

Evidence

Clinical trials

Class

Long-acting GLP-2 receptor agonist

/

Apraglutide

KEY TAKEAWAY

Apraglutide is a long-acting GLP-2 analog designed for once-weekly dosing. It is being developed for short bowel syndrome. Apraglutide is not FDA-approved and has been tested in late-stage clinical trials.

Written by the Veylo editorial team · Updated

November 2026

At a glance

At a glance

What it is

Long-acting GLP-2 receptor agonist

Being studied for

Studied in short bowel syndrome with intestinal failure

Key fact

Apraglutide is not FDA-approved and has been tested in late-stage clinical trials.

Route

Weekly subcutaneous injection in trials

Evidence strength

Clinical trials

What it is

What it is

Apraglutide is a long-acting GLP-2 analog designed for once-weekly dosing. It is being developed for short bowel syndrome.

How it works

How it works

It activates GLP-2 receptors to support growth of the intestinal lining and improve absorption.

Regulatory status

Regulatory status

Apraglutide is not FDA-approved and has been tested in late-stage clinical trials.

What it is used for

What it is used for

Studied in short bowel syndrome with intestinal failure.

Side effects and risks

Side effects and risks

Reported effects include abdominal pain, swelling and nausea. Growth of the gut lining requires monitoring.

Citations

Citations

Apraglutide: see PubMed and ClinicalTrials.gov for published studies and registered trials. No FDA drug label exists for the uses described.

Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.

Veylo

Clinician-guided peptide care, paired with baseline blood testing and ongoing support.

Peptides referenced on this site are compounded medications and are investigational; they have not been approved by the FDA for the uses described. Nothing here is medical advice. Prescriptions are issued only after a licensed clinician reviews your history.

© 2026 Veylo. All rights reserved.

Veylo

Veylo

Veylo